Home > Insider Trading > Filing (0001209191-22-015555)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1805890	Fusion Pharmaceuticals Inc.	FUSN	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1813574	John Valliant	C/O Fusion Pharmaceuticals, Inc. 2 International Place, Suite 2310 Boston MA 02110	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2022-03-01	847	$7.37	431,536	No	4	S	Direct
Common Stock	Disposition	2022-03-02	26,546	$7.44	404,990	No	4	S	Direct
Common Stock	Disposition	2022-03-03	200	$7.28	404,790	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $7.29 to $7.52 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $7.20 to $7.60 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $7.28 to $7.281 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.